top of page
Browse by category
Search
Adults with pre-diabetes and obesity or overweight treated with tirzepatide had sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
Results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide,...
Tirzepatide reduced the risk of developing T2Dm by 94% in adults with pre-diabetes and obesity or overweight
Eli Lilly and Company has announced positive topline results from the SURMOUNT-1 three-year study (176-week treatment period) evaluating...
Tirzepatide may help lower blood pressure in adults with obesity
Tirzepatide significantly lowered the systolic blood for nearly 500 adults with obesity who took the medication for about eight months,...
SURMOUNT-1: Tirzepatide results in 22.5% weight loss in adults with obesity or overweight
Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli...
Browse by tag
bottom of page